Here, we presented an albumin-based biomimetic delivery system for codelivery of the disulfiram/copper complex (DSF/Cu) and the macrophage modulator regorafenib (Rego) via a so-called “two-birds-one-stone” strategy for targeting both glioma cells and TAM2. This evidence concerns the gene ALB and central nervous system cancer.